NYSE:HUM - Humana Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$309.35 +1.79 (+0.58 %)
(As of 02/22/2019 04:00 PM ET)
Previous Close$307.56
Today's Range$306.28 - $311.24
52-Week Range$261.35 - $355.88
Volume26,343 shs
Average Volume931,763 shs
Market Capitalization$41.94 billion
P/E Ratio21.28
Dividend Yield0.32%
Beta1.05
Humana Inc., together with its subsidiaries, operates as a health and well-being company in the United States. The company operates through four segments: Retail; Group and Specialty; Healthcare Services; and Individual Commercial. The Retail segment offers Medicare and supplemental benefit plans to individuals or through group accounts. This segment also has contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits. The Group and Specialty segment provides commercial fully-insured medical and specialty health insurance benefits comprising dental, vision, and other supplemental health and voluntary insurance benefits; financial protection products; and administrative services only products to individuals and employer groups. It also offers military services, such as TRICARE South Region contract. The Healthcare Services segment provides pharmacy solutions, provider services, predictive modeling and informatics services, and clinical care services, such as home health and other services to its health plan members, as well as to third parties. The Individual Commercial segment offers individual commercial fully-insured medical health insurance benefits under the HumanaOne brand. The company also provides closed-block long-term care insurance policies. As of December 31, 2017, it had approximately 14 million members in medical benefit plans, as well as approximately 7 million members in specialty products. Humana Inc. was founded in 1961 and is headquartered in Louisville, Kentucky.

Receive HUM News and Ratings via Email

Sign-up to receive the latest news and ratings for HUM and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Hospital & medical service plans
Sub-IndustryManaged Health Care
SectorMedical
CUSIP44485910
Phone502-580-1000

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$56.91 billion
Cash Flow$18.8284 per share
Book Value$74.95 per share

Profitability

Net Income$1.68 billion

Miscellaneous

Employees45,900
Market Cap$41.94 billion
Next Earnings Date5/1/2019 (Estimated)
OptionableOptionable

Humana (NYSE:HUM) Frequently Asked Questions

What is Humana's stock symbol?

Humana trades on the New York Stock Exchange (NYSE) under the ticker symbol "HUM."

How often does Humana pay dividends? What is the dividend yield for Humana?

Humana announced a quarterly dividend on Friday, February 8th. Investors of record on Friday, March 29th will be paid a dividend of $0.55 per share on Friday, April 26th. This represents a $2.20 dividend on an annualized basis and a yield of 0.71%. The ex-dividend date is Thursday, March 28th. This is a boost from Humana's previous quarterly dividend of $0.50. View Humana's Dividend History.

How will Humana's stock buyback program work?

Humana declared that its Board of Directors has authorized a share repurchase program on Friday, December 15th 2017, which permits the company to buyback $3,000,000,000.00 in shares, according to EventVestor. This buyback authorization permits the company to repurchase shares of its stock through open market purchases. Stock buyback programs are typically a sign that the company's board believes its shares are undervalued.

How were Humana's earnings last quarter?

Humana Inc (NYSE:HUM) posted its quarterly earnings results on Wednesday, February, 6th. The insurance provider reported $2.65 EPS for the quarter, topping the Thomson Reuters' consensus estimate of $2.53 by $0.12. The insurance provider had revenue of $14.17 billion for the quarter, compared to analysts' expectations of $14.04 billion. Humana had a return on equity of 19.64% and a net margin of 2.96%. The company's revenue for the quarter was up 7.4% compared to the same quarter last year. During the same quarter in the previous year, the company posted $2.06 earnings per share. View Humana's Earnings History.

When is Humana's next earnings date?

Humana is scheduled to release their next quarterly earnings announcement on Wednesday, May 1st 2019. View Earnings Estimates for Humana.

What guidance has Humana issued on next quarter's earnings?

Humana issued an update on its FY19 earnings guidance on Wednesday, February, 6th. The company provided earnings per share (EPS) guidance of $17.00-17.50 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $17.48. Humana also updated its FY 2019 guidance to $17.00-17.50 EPS.

What price target have analysts set for HUM?

16 analysts have issued 12-month target prices for Humana's shares. Their predictions range from $275.02 to $418.00. On average, they expect Humana's share price to reach $357.0013 in the next twelve months. This suggests a possible upside of 15.4% from the stock's current price. View Analyst Price Targets for Humana.

What is the consensus analysts' recommendation for Humana?

16 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Humana in the last year. There are currently 3 hold ratings and 13 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Humana.

What are Wall Street analysts saying about Humana stock?

Here are some recent quotes from research analysts about Humana stock:
  • 1. According to Zacks Investment Research, "Humana’s fourth-quarter operating earnings per share of $2.65 beat the Zacks Consensus Estimate by 4.7% and also improved 28.6% year over year. This upside can primarily be attributed to Medicare Advantage membership growth and significant operating efficiency. The company is well-poised for growth on the back of its strong Medicare business. Its top line has been witnessing an uptrend for the past several years. Acquisitions and dispositions made by the company have also led to business growth over the last few quarters. However, its shares have underperformed its industry’s in a year’s time. Its rising level of expenses since 2010 persistently weighs on the bottom line. The company expects high benefit expenses which will lead to an overall increase in operating expenses going forward. " (2/8/2019)
  • 2. Cantor Fitzgerald analysts commented, ". We reiterate our Neutral rating on HUM shares and maintain our 12-month price target of $325. After the market close on the company reaffirmed its 2018 EPS guidance. The company also provided updated 2019 membership metrics. Given the update, we are increasing our 2019 revenue and EPS estimates. The company had previously indicated that it expected 2019 adjusted EPS to grow above its stated long-term goal of 11-15%. With its filing on Wednesday, the company did not comment on 2019 EPS guidance, but will provide detailed 2019 financial guidance when it reports 4Q18 and year-end 2018 results on Wednesday, February 6, 2019." (1/2/2019)

Has Humana been receiving favorable news coverage?

News headlines about HUM stock have been trending somewhat positive recently, InfoTrie reports. InfoTrie identifies positive and negative press coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Humana earned a coverage optimism score of 1.7 on InfoTrie's scale. They also assigned media coverage about the insurance provider a news buzz of 4.0 out of 10, meaning that recent press coverage is somewhat unlikely to have an impact on the stock's share price in the near future.

Who are some of Humana's key competitors?

What other stocks do shareholders of Humana own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Humana investors own include UnitedHealth Group (UNH), Alibaba Group (BABA), Boeing (BA), Netflix (NFLX), NVIDIA (NVDA), General Electric (GE), Visa (V), Gilead Sciences (GILD), Mastercard (MA) and Walt Disney (DIS).

Who are Humana's key executives?

Humana's management team includes the folowing people:
  • Mr. Bruce Dale Broussard, Pres, CEO & Director (Age 57)
  • Mr. Brian Andrew Kane, Sr. VP & CFO (Age 46)
  • Mr. Timothy S. Huval, Chief HR Officer (Age 53)
  • Ms. Jody L. Bilney, Chief Consumer Officer (Age 58)
  • Ms. Cynthia Hillebrand Zipperle, Sr. VP, Chief Accounting Officer & Controller (Age 56)

Who are Humana's major shareholders?

Humana's stock is owned by many different of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (8.75%), Bank of America Corp DE (1.68%), Newport Trust Co (1.29%), Geode Capital Management LLC (1.29%), Northern Trust Corp (1.26%) and Dimensional Fund Advisors LP (0.98%). Company insiders that own Humana stock include Brian P Leclaire, Bruce D Broussard, Christopher H Hunter, Cynthia H Zipperle, David A Jr/Ky Jones, Elizabeth D Bierbower, Heidi S Margulis, James E Murray, Jody L Bilney, M Todoroff Christopher, Roy A Beveridge, Timothy Alan Wheatley, Timothy S Huval and William Kevin Fleming. View Institutional Ownership Trends for Humana.

Which institutional investors are selling Humana stock?

HUM stock was sold by a variety of institutional investors in the last quarter, including BlackRock Inc., Orbimed Advisors LLC, Bank of Montreal Can, Bank of New York Mellon Corp, Robeco Institutional Asset Management B.V., Nuveen Asset Management LLC, Mackay Shields LLC and Acadian Asset Management LLC. Company insiders that have sold Humana company stock in the last year include Bruce D Broussard, Christopher H Hunter, Cynthia H Zipperle, David A Jr/Ky Jones, Elizabeth D Bierbower, Heidi S Margulis, Jody L Bilney, M Todoroff Christopher, Roy A Beveridge, Timothy Alan Wheatley and William Kevin Fleming. View Insider Buying and Selling for Humana.

Which institutional investors are buying Humana stock?

HUM stock was acquired by a variety of institutional investors in the last quarter, including Millennium Management LLC, Ceredex Value Advisors LLC, Geode Capital Management LLC, Boston Partners, AMF Pensionsforsakring AB, California Public Employees Retirement System, Northern Trust Corp and Partner Fund Management L.P.. View Insider Buying and Selling for Humana.

How do I buy shares of Humana?

Shares of HUM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Humana's stock price today?

One share of HUM stock can currently be purchased for approximately $309.35.

How big of a company is Humana?

Humana has a market capitalization of $41.94 billion and generates $56.91 billion in revenue each year. The insurance provider earns $1.68 billion in net income (profit) each year or $14.55 on an earnings per share basis. Humana employs 45,900 workers across the globe.

What is Humana's official website?

The official website for Humana is http://www.humana.com.

How can I contact Humana?

Humana's mailing address is 500 West Main Street, LOUISVILLE KY, 40202. The insurance provider can be reached via phone at 502-580-1000 or via email at [email protected]


MarketBeat Community Rating for Humana (NYSE HUM)

Community Ranking:  2.4 out of 5 (star star)
Outperform Votes:  706 (Vote Outperform)
Underperform Votes:  760 (Vote Underperform)
Total Votes:  1,466
MarketBeat's community ratings are surveys of what our community members think about Humana and other stocks. Vote "Outperform" if you believe HUM will outperform the S&P 500 over the long term. Vote "Underperform" if you believe HUM will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/22/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel